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Sevelamer: Where are
the data?
To the Editor: In their study of sevelamer versus
calcium-based phosphate binders in hemodialysis pa-
tients, Chertow et al [1], in a recent issue of Kidney In-
ternational concluded that sevelamer attenuates vascular
calcifications while maintaining good phosphorus con-
trol. The implications of this claim are exemplified by
the aggressive marketing efforts of this study’s sponsor,
Genzyme Corporation [2].
Canavese et al [3] raised critical statistical issues re-
garding the study in their subsequent letter to Kidney
International. They noted that “the patients cited in
Tables 3 and 4 . . . are not the same,” and that “multivari-
ate analysis of the role of hypercalcemia and hypercal-
cemic episodes in the progression of calcification” was
not provided. Neither point was addressed in the authors’
reply [4].
The means and standard deviations of baseline electron
beam tomography (EBT) scores (Table 3) document that
score distributions were not comparable between groups.
Furthermore, ∼30% of the baseline cohort was excluded
from the 26- and 52-week analyses. Without baseline dis-
tribution of EBT scores for the actual population ana-
lyzed, absolute or percentage changes cannot be deter-
mined. Further weakening the validity of this study’s find-
ings are the absence of evidence of the reproducibility of
the EBT measurements and the failure to make appro-
priate statistical adjustments for subjects who dropped
out of the study (Table 3, footnote). Those adjustments
may reveal that even the primary end point, phosphorus
control, was not achieved.
With provision of the data requested here and by
Canavese, reanalysis may likely determine that there
were no differences between absolute EBT scores of the
two groups or in the changes in the 52-week EBT scores.
Until these additional data are published in a transpar-
ent fashion, the authors’ claim that sevelamer attenuates
cardiovascular calcification remains purely speculative.
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Milking the sevelamer-calcium debate
We are delighted that the results of our randomized
clinical trial comparing calcium-based phosphate binders
with sevelamer [1] continue to be of interest to readers
of Kidney International, prompting Letters to the Editor
more than one year after the publication date. It is es-
pecially gratifying to read such a letter from Professor
McCarron, a leading researcher who has published more
than 200 articles over the past 20 years, including more
than 150 on the topic of calcium.
Professor McCarron correctly summarized our conclu-
sion, that relative to calcium salts, sevelamer attenuated
the progression of coronary artery and aortic calcifica-
tion, and indeed, sevelamer (and calcium) provided good
control of serum phosphorus. Our initial reply to four let-
ters to the Editor was necessarily brief; the major issues
raised by Canavese et al [2] and other authors were ad-
dressed [3]. Herein we provide additional requested data.
If one were to consider only those 150 study subjects
who underwent a follow-up electron beam tomography
(EBT) scan, the baseline median (interquartile range)
coronary artery calcium scores were 665 (79 to 2250) and
578 (76 to 1294) in the sevelamer- and calcium-treated
subjects, respectively (P = 0.30). Corresponding median
(interquartile range) aortic calcium scores were 668 (25
to 3662) and 360 (4 to 4030) (P = 0.61). These results are
similar to the results for all study subjects who underwent
baseline EBT scanning (N = 186) reported in Table 3.
Among calcium-treated subjects, the changes in
coronary artery and aortic calcification were directly
correlated with the time-averaged serum calcium concen-
tration (r = 0.18 and r = 0.28, respectively). The median
changes in calcification were significantly higher when
the time-averaged serum calcium concentrations were
greater than or equal to 9.5 mg/dL.
Professor McCarron claims that the validity of the
study is weakened by the “absence of evidence of re-
producibility of the EBT measurements.” Indeed, in the
manuscript we stated “the median inter-scan variability
is 8% to 10% for the Agatston score” and we provided
supporting references. Professor McCarron also contends
that we failed to “make appropriate statistical adjust-
ments for subjects who dropped out of the study” and
that “those adjustments may reveal that even the primary
endpoint, phosphorus control, was not achieved.” In the
manuscript we stated that “all laboratory analyses were
performed using a last value carried forward approach,” a
conservative method commonly used to account for the
analysis of continuous variables in a longitudinal study
